Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Chronic Intestinal Inflammation and Cancers (2nd Edition)
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Chronic Intestinal Inflammation and Cancers (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".

Deadline for manuscript submissions: 20 February 2026 | Viewed by 4222

Special Issue Editors

Prof. Dr. Livia Biancone

E-Mail Website
Guest Editor
1. Gastroenterology Unit, Department of Systems Medicine, University “Tor Vergata” of Rome, 00133 Roma, Italy
2. Department of Medical Science, University “Tor Vergata” of Rome, 00133 Roma, Italy
Interests: inflammatory bowel disease; IBD-associated cancer.
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. David Laharie

E-Mail Website
Guest Editor
CHU de Bordeaux, Centre Médico-Chirurgical Magellan, Hôpital Haut-Lévêque, Gastroenterology Department, Université de Bordeaux, INSERM CIC 1401, 33000 Bordeaux, France
Interests: inflammatory bowel disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the previous Special Issue entitled "Chronic Intestinal Inflammation and Cancers".

It is well known that inflammation-associated colorectal cancer shows different clinicopathological characteristics compared to sporadic colorectal cancer. These include a younger age at diagnosis, a worse outcome, and a different molecular pathway (which more frequently includes mutation on the TP53 gene). Moreover, in inflammatory bowel disease, higher frequencies of signet rings and mucinous adenocarcinomas have been suggested. Furthermore, when focusing on precancerous chronic inflammation-associated lesions, it has been shown that these are more frequently non-polypoid and present in patients with inflammatory bowel diseases and are thus more difficult to detect during screening colonoscopies. Chromoendoscopy, which is able to enhance polyp detection, currently represents the gold standard technique for colorectal cancer screening in these patients, thus allowing a better characterization of the lesions. A wider application of advanced endoscopic resection techniques is therefore achieved using this technique.

Chronic inflammation leading to small bowel cancer has also been described in the development of cancers complicating coeliac disease and Crohn’s disease. Different molecular pathways and risk factors have been described in these conditions. The role of immunomodulators in determining the risk of cancer in patients with a prior history of cancer is still debated, particularly in inflammatory bowel disease and in patients often requiring conventional immunosuppressives or biologic therapies for the underlying chronic intestinal inflammation.

We are pleased to invite you to contribute to the Special Issue “Chronic intestinal inflammation and cancers”. The aim of the present Special Issue is to summarize current evidence and possibly to increase the knowledge in the field of intestinal cancers associated with chronic inflammation. We aim to report and to investigate evidence regarding inflammation-associated intestinal cancers from its precursors to patient outcomes. For this purpose, we will collect at least 10 articles. The Special Issue may be printed in book form if this number is reached.

This Special Issue aims to deepen knowledge in the field of intestinal cancers associated with chronic inflammation.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Intestinal cancers associated with chronic inflammation and outcomes;
  • Intestinal cancer associated with chronic inflammation: molecular pathway;
  • Colorectal cancer associated with chronic inflammation and cancer precursors: diagnosis and management;
  • Immunomodulators in patients with a prior history of cancer;
  • Intestinal cancers associated with chronic inflammation: epidemiology and histological characterization;
  • Colorectal cancer and small bowel cancer in inflammatory bowel disease;
  • Small intestinal cancer and coeliac disease.

We look forward to receiving your contributions.

Prof. Dr. Livia Biancone
Prof. Dr. David Laharie
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • chronic inflammation
  • inflammatory bowel disease
  • inflammation-associated dysplasia
  • outcomes
  • cancer molecular pathways

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

18 pages, 362 KB  
Article
Inflammatory Bowel Disease Patients with a History of Cancer: Safety of Immunomodulators in a Multicenter Study
by Roberto Mancone, Benedetto Neri, Clara De Francesco, Livio Bonacci, Mariasofia Fiorillo, Sara Concetta Schiavone, Anna Galbusera, Alba Sparacino, Anna Testa, Ambrogio Orlando, Emma Calabrese, Irene Marafini, Stefano Festa, Fabiana Castiglione, Walter Fries, Giovanni Monteleone and Livia Biancone
Cancers 2025, 17(20), 3293; https://doi.org/10.3390/cancers17203293 - 11 Oct 2025
Viewed by 327
Abstract
Introduction: The risk of new or recurrent cancer in inflammatory bowel disease (IBD) patients with a history of cancer treated with immunomodulators (IMMs), including conventional immunosuppressors (ISSs), biologics or small molecules is undefined. The primary aim was to assess the frequency of [...] Read more.
Introduction: The risk of new or recurrent cancer in inflammatory bowel disease (IBD) patients with a history of cancer treated with immunomodulators (IMMs), including conventional immunosuppressors (ISSs), biologics or small molecules is undefined. The primary aim was to assess the frequency of new or recurrent cancer in IBD patients treated with IMMs after first cancer. The secondary aim was to evaluate risk factors for new/recurrent cancer in the same IBD population. Methods: In a retrospective multicenter study, all IBD patients using any IMM after first (index) cancer were enrolled. Inclusion criteria: Crohn’s disease (CD) or ulcerative colitis (UC), history of any cancer, detailed clinical history, and follow-up after cancer of ≥6 months. Exclusion criteria: IMM use for ≤3 months. Results: In total, 122 IBD patients (84 CD, 38 UC) treated with IMMs after first cancer were enrolled (age 59.5 [26–89] years). Index cancer included (n = [%]) genitourinary tract cancer (18 [14.8]), non-melanotic skin cancer (NMSC) (17 [13.9]), breast cancer (15 [12.3]), thyroid cancer (13 [10.7]), melanoma (14 [11.4]), colorectal cancer (CRC) (11 [9.0]), hematopoietic cancer (9 [7.4]), prostatic cancer (8 [6.6]), neuroendocrine cancer (4 [3.3]), head and neck cancer (3 [2.5]), liver cancer (3 [2.5]), endometrium cancer (2 [1.6]), lung cancer (1 [0.8]) and others (3 [2.5]). ISSs after cancer included (n = [%]) thiopurines (10 [37]), methotrexate (MTX) (14 [51.9]) and others (3 [11.1]) Biologics included (n = [%]) TNF-inhibitors (36 [32.4]), vedolizumab (60 [53.6]), ustekinumab (45 [40.2]), small molecules (9 [7.3]) and others (6 [5.4]). In a median follow-up of 8 [1–45] years after index cancer, 12/122 (9.8%) patients using IMMs after cancer developed new or recurrent cancer. No risk factors for new/recurrent cancer (i.e., age at diagnosis of cancer, smoke, gender, IBD type, IMM use, duration before or after cancer) were identified. Conclusions: In a multicenter study, ISSs or biologics after cancer were not identified as risk factors for new or recurrent cancer in IBD. However, IMMs were used after a long-term interval from index cancer. Full article
(This article belongs to the Special Issue Chronic Intestinal Inflammation and Cancers (2nd Edition))
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 306 KB  
Review
Management of Inflammatory Bowel Disease with History of Cancer
by Vito Annese, Marzio Parisi, Sofia Cinque, Alessandro Cappellini, Paolo Biamonte, Giuseppe Dell’Anna, Sabrina Gloria Giulia Testoni and Maria Laura Annunziata
Cancers 2025, 17(21), 3475; https://doi.org/10.3390/cancers17213475 - 29 Oct 2025
Viewed by 233
Abstract
Background/Objectives: Because of the chronic course of the disease, clinicians managing IBD frequently encounter patients with a prior or newly diagnosed cancer. This can be related to the specific background cancer risk in that subject, aging, familial/genetic factors, or ongoing chronic inflammation. [...] Read more.
Background/Objectives: Because of the chronic course of the disease, clinicians managing IBD frequently encounter patients with a prior or newly diagnosed cancer. This can be related to the specific background cancer risk in that subject, aging, familial/genetic factors, or ongoing chronic inflammation. However, a potential influence of some therapeutic agents should also be considered. This setting, in the absence of controlled trials and few open series reports available, raises issues such as correct screening, prevention, and surveillance, but also eventual modification or adaptation of the medical management. Methods and Results: Few consensus guidelines and studies are available on the management of IBD patients with a history of cancer, and therefore, we aim to review the recommendations of the current guidelines and the evidence reported in the most recent real-world cohorts. Conclusions: This review will offer (a) an understanding of the background of cancer risk in IBD patients; (b) analysis and discussion of the risk of cancer related to IBD therapy; and, finally, (c) some clues for the management of IBD in patients with a previous or current history of cancer. Full article
(This article belongs to the Special Issue Chronic Intestinal Inflammation and Cancers (2nd Edition))
27 pages, 21074 KB  
Review
Colitis-Associated Dysplasia in Inflammatory Bowel Disease: Features and Endoscopic Management
by Sara C. Schiavone, Livia Biancone, Mariasofia Fiorillo, Andrea Divizia, Roberto Mancone and Benedetto Neri
Cancers 2025, 17(5), 784; https://doi.org/10.3390/cancers17050784 - 25 Feb 2025
Viewed by 3219
Abstract
Patients with long-standing inflammatory bowel disease (IBD) involving the colon are at higher risk of developing colorectal dysplastic or neoplastic lesions. While from sporadic colorectal cancer follows an “adenoma-carcinoma” sequence, IBD colitis-associated carcinogenesis is mainly related to an “inflammation-dysplasia-carcinoma” sequence. Currently, specific endoscopic [...] Read more.
Patients with long-standing inflammatory bowel disease (IBD) involving the colon are at higher risk of developing colorectal dysplastic or neoplastic lesions. While from sporadic colorectal cancer follows an “adenoma-carcinoma” sequence, IBD colitis-associated carcinogenesis is mainly related to an “inflammation-dysplasia-carcinoma” sequence. Currently, specific endoscopic surveillance strategies involving dye spray and virtual chromoendoscopy have been standardized, aiming for early CRC diagnosis. When detected, colitis-associated dysplasia should be classified according to standard classification, thus allowing for better treatment. Indeed, most IBD-associated dysplastic lesions can be treated with endoscopic resection, even though available procedures are usually more challenging than those in the general population. The higher frequency of severe submucosal fibrosis and the difficulty in the definition of lesions’ margins account for this issue. Current endoscopic resection techniques include polypectomy, endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). Recent evidence suggests the relevance of en bloc resection, as this may be associated with lower rates of recurrence. Therefore, particularly for larger (>20 mm) lesions, ESD should be preferred, even though it is considered the most difficult technique due to frequent severe submucosal fibrosis. Considering the growing number of new endoscopic resective techniques, including underwater EMR or ESD, which in the general population have been suggested to lower procedure-related risks and may also allow a larger spread of advanced endoscopic resection in IBD. However, additional data are needed to assess the medium- and long-term efficacy of endoscopic resection of visible dysplasia in IBD patients, which are burdened by a high risk of local and, more importantly, metachronous recurrence. Full article
(This article belongs to the Special Issue Chronic Intestinal Inflammation and Cancers (2nd Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop